The paper presents immediate and long-term results of early invasive treatment tactics in 467 patients with various forms of unstable angina (UA), including 129 patients with unstable rest angina, 225 patients with unstable exertional angina, and 93 patients with a new onset angina. Percutaneous coronary interventions on a symptom-affected artery at a single procedure were performed in 213 cases (48%), indications for coronary artery bypass grafting were identified in 182 patients (41%), and only in 52 cases (11%) the treatment was limited to medicinal therapy. Coronary angiography performed in the initial 12–48 hours makes it possible to identify the indications to myocardial revascularization, to avoid inconsistencies in the choice of optimal treatment tactics and non-invasive risk assessment.

The literature review presents current international data on the principles of choice of hypotensive therapy tactics in patients with chronic kidney disease and glomerulonephritis. safe levels of blood pressure reduction, reflected in the regulatory documents of European and American nephrological and cardiological associations, methods of their control are discussed. Data on the nephroprotective effects of the main classes of hypotensive drugs – angiotensin-converting enzyme inhibitors and angiotensin receptor blockers – are presented. The necessity of monitoring the safety of hypotensive therapy in glomerulonephritis with chronic kidney disease using methods of blood pressure monitoring is emphasized.

The article presents the results of video laparoscopy (VLS) performed in 2008–2019 in 5,599 patients in order to diagnose acute diseases of the abdominal organs requiring emergency surgery, identify competing and concomitant diseases, and determine treatment tactics. 2,442 (43.6 %) of them made up group I, with no doubt; 2,656 (47.4 %) – II group, with presumptive reliability; and 501 (9.0 %) – group III, with an unclear clinical diagnosis of the disease. In 2,326 (95.2 %) patients of group I with VLS, the clinical diagnosis was confirmed, in 100 (4.1 %) other diseases were revealed, and in 16 (0.7 %) the diagnosis was not established. Competing diseases were found in 8 patients and concomitant diseases in 4. In 1,641 (61.8 %) patients of group II, VLS made it possible to clarify and differentiate the clinical diagnosis of diseases, in 929 (35.0 %) – to identify other diseases, and in 86 (3.2 %) the diagnosis was not possible. When performing differential diagnosis, 126 other diseases were identified more than the number of patients. Competing diseases were found in 6 patients and concomitant diseases in 6 patients. 356 (71.0 %) patients of group III with VLS were diagnosed with major diseases, 75 (15.0 %) had other diseases, and 70 (14.0 %) were not diagnosed. In 4 patients, competing diseases were found, and in 1 – concomitant disease. Of the 5,427 (96.9 %) patients with the definitive diagnosis of the disease established with VLS, 3,828 (70.5 %) were found to be able to perform VLS operations, in 10 (0.3 %) of them – simultaneous with competing diseases.

The paper summarizes data on modern approaches to the diagnosis, prevention and treatment of severe acute parenchymal respiratory failure of various origins, including ARDS due to bacterial viral pneumonia. The work is based on the data of modern well-organized studies, analysis of international clinical guidelines with a high degree of evidence, as well as the results of our own long-term experimental studies and clinical observations of the treatment of patients with ARDS of various origins, including viral pneumonia of 2009, 2016, 2020. Scientifically grounded algorithms for prevention, differential diagnosis and personalized therapy of severe acute respiratory failure using innovative medical technologies and a wide range of respiratory and adjuvant treatment methods have been formulated. The authors tried to adapt as much as possible the existing current recommendations for the daily clinical practice of anesthesiologists and resuscitators.

The paper summarizes data on modern approaches to the diagnosis, prevention and treatment of severe acute parenchymal respiratory failure of various origins, including ARDS due to bacterial viral pneumonia. The work is based on the data of modern well-organized studies, analysis of international clinical guidelines with a high degree of evidence, as well as the results of our own long-term experimental studies and clinical observations of the treatment of patients with ARDS of various origins, including viral pneumonia of 2009, 2016, 2020. Scientifically grounded algorithms for prevention, differential diagnosis and personalized therapy of severe acute respiratory failure using innovative medical technologies and a wide range of respiratory and adjuvant treatment methods have been formulated. The authors tried to adapt as much as possible the existing current recommendations for the daily clinical practice of anesthesiologists and resuscitators.

Malnutrition is an unfavorable background for the course and outcome of viral diseases, including COVID-19. In accordance with international recommendations, timely correction of nutritional status using oral, tube enteral and parenteral nutrition is a necessary and mandatory method of concomitant therapy for COVID-19. An analytical review of the results of studies on the clinical use of pharmacological nutrients (glutamine; vitamins A, C, D, E; zinc, selenium) for the prevention and treatment of viral infections, including COVID-19, was performed. According to the data of clinical studies carried out in 2019–2020, the use of glutamine and antioxidant micronutrients as part of nutritional metabolic therapy can reduce the severity of clinical symptoms and accelerate the recovery process of patients with the new coronavirus infection COVID-19 and other viral diseases. From a practical point of view, the only sources of glutamine for enteral administration registered in the Russian Federation are Glutamine Plus for oral enteral nutrition and Intestamin for enteral tube administration and Dipeptiven 20% for parenteral nutrition. The use of pharmacological nutritional therapy, in particular, enteral or parenteral glutamine as a component of clinical nutrition in patients with viral infections and nutritional deficiency or the risk of its development, helps to improve clinical results, reduce the severity of the disease and accelerate the rehabilitation process.